Mandatory notification of trade

08. May 2025 | 1 min read

Moss, 8 May 2025

Gentian Diagnostics ASA ("Gentian") has today been notified that the following transaction has been completed:

Norda ASA has purchased 101,848 shares in Gentian at NOK 51.50 per share. Following the transaction Norda ASA owns 716,099 shares in Gentian. Norda ASA owns about 4.64% of the total outstanding shares following the transaction. Norda ASA will together with the Group of companies Kvantia AS, Obligasjon 2 AS, Caaby AS, RWD AS, Insr ASA and Victoria India Fund AS following the share transaction hold in total 3,524,218 shares in Gentian, corresponding to approx. 22.85% of the total outstanding shares.

Christian Åbyholm is Chairman of the Board of Norda ASA and is a Member of the Board of Directors and primary insider in Gentian.

PCA notification pursuant to the EU Market Abuse Regulation Article 19 is attached.

This information is subject to the disclosure requirements pursuant to Section 5-12 of the Norwegian Securities Trading Act, EU Market Abuse Regulation Article 19 and Euronext Oslo Rule Book II.

 

For further information, please contact:

Njaal Kind, Group CFO
njaal.kind@gentian.no

+47 91 90 65 25

You may also read


Mar 20, 2026 - Ole Sørlie

Gentian Diagnostics: Annual report 2025

Moss, 20 March 2026 Gentian Diagnostics has today published its annual report for 2025. The annual report and..

Mar 12, 2026 - Ole Sørlie

Gentian Diagnostics ASA – Employee Share Purchase Program and share capital increase

Moss, 12 March 2026 Gentian Diagnostics ASA (the "Company") has completed the offer of new shares to..